BACKGROUND: Rheohemapheresis (RHF) is a method that can stop the activity of the dry form of age-related macular degeneration (AMD). The pathophysiologic mechanisms are not well understood, and the effects of the RHF procedures extend beyond the time of the individual procedures. PATIENTS AND METHODS: We present the data for 46 patients with AMD treated with a series of 8 rheohemapheretic procedures. Blood count parameters were measured before the first and the last procedures. The clinical effect was judged by changes in the drusenoid pigment epithelium detachment (DPED) area before and after the rheopheretic sessions. RESULTS: Rheopheresis caused a decrease in hemoglobin (P<0.001), a decrease in leukocytes (P<0.034), and an increase in platelets (P<0.005). We found a negative correlation between the amount of platelets and their volume (P<0.001, Pearson correlation coefficient: -0.509). We identified the platelet/MPV ratio as a good predictor of the clinical outcome. Patients with a platelet/MPV ratio greater than 21.5 (before the last rheopheresis) had a significantly better outcome (P=0.003, sensitivity of 76.9% and specificity of 80%). CONCLUSION: Several basic blood count parameters after RHF can be concluded to significantly change, with some of those changes correlating with the clinical results (reduction of the DPED area).

4th Department of Internal Medicine Hematology Faculty Hospital Faculty of Medicine in Hradec Králové Charles University Prague Sokolska Street 581 500 05 Hradec Králové Czech Republic

Department of Ophthalmology Faculty Hospital Faculty of Medicine in Hradec Králové Charles University Prague Sokolska Street 581 500 05 Hradec Králové Czech Republic

Zobrazit více v PubMed

Fell AJ, Engelmann K, Richard G, Fassbender C, Wahls W, Klingel R. A systematic approach to therapy of age-related macular degeneration (AMD)? Ophthalmologe. 2002;99(10):780–784. PubMed

Klein R, Chou C, Klein BEK, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Archives of Ophthalmology. 2011;129(1):75–80. PubMed

Michalska-Malecka K, Slowinska L, Dorecka M, Romaniuk W. Correlations in some pathogenetic factors and values of hemorheological parameters in age-related macular degeneration. Clinical Hemorheology and Microcirculation. 2008;38(3):209–216. PubMed

Klingel R, Fassbender C, Faßbender T, Göhlen B. Clinical studies to implement Rheopheresis for age-related macular degeneration guided by evidence-based-medicine. Transfusion and Apheresis Science. 2003;29(1):71–84. PubMed

Klingel R, Erdtracht B, Gauss V, Piazolo A, Mausfeld-Lafdhiya P, Diehm C. Rheopheresis in patients with critical limb ischemia—results of an open label prospective pilot trial. Therapeutic Apheresis and Dialysis. 2005;9(6):473–481. PubMed

Klingel R, Fassbender C, Fassbender T, Erdtracht B, Berrouschot J. Rheopheresis: rheologic, functional, and structural aspects. Therapeutic Apheresis. 2000;4(5):348–357. PubMed

Klingel R, Fassbender C, Heibges A, et al. RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Therapeutic Apheresis and Dialysis. 2010;14(3):276–286. PubMed

Rencová E, Bláha M, Studnicka J, et al. Reduction in the drusenoid retinal pigment epithelium detachment area in the dry form of age-related macular degeneration 2. 5 years after rheohemapheresis. Acta Ophthalmologica. 2013;91(5):e406–e408. PubMed

Bláha M, Rencová E, Langrova H, et al. The importance of rheological parameters in the therapy of the dry form of age-related macular degeneration with rheohaemapheresis. Clinical Hemorheology and Microcirculation. 2012;50(4):245–255. PubMed

Rencová E, Bláha M, Studnička J, et al. Haemorheopheresis could block the progression of the dry form of age-related macular degeneration with soft drusen to the neovascular form. Acta Ophthalmologica. 2011;89(5):463–471. PubMed

Bláha M, Cermanova M, Bláha V, et al. Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis. 2008;197(1):264–270. PubMed

Ramunni A, Brescia P, de Fino G, Piscopo G, Gesualdo L. Therapeutic apheresis in peripheral and retinal circulatory disorders. Clinical Research in Cardiology Supplements. 2012;7(supplement 1):41–44. PubMed PMC

Borberg H, Tauchert M. Rheohaemapheresis of ophthalmological diseases and diseases of the microcirculation. Transfusion and Apheresis Science. 2006;34(1):41–49. PubMed

Otto C, Richter WO, Schwandt P. Contribution of fibrinogen and lipoproteins to plasma viscosity in hypercholesterolemia and hypertriglyceridemia: evaluation by selective depletion of low-density lipoproteins or fibrinogen. Metabolism. 2000;49(6):810–813. PubMed

Koss MJ, Kurz P, Tsobanelis T, et al. Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2009;247(10):1297–1306. PubMed

Yeh J, Cheng C, Chiu H. A case report of double-filtration plasmapheresis for the treatment of age-related macular degeneration. Therapeutic Apheresis and Dialysis. 2008;12(6):500–504. PubMed

Ramunni A, Burzo M, Vernò L, Brescia P. Pleiotropic effects of LDL apheresis. Atherosclerosis Supplements. 2009;10(5):53–55. PubMed

Ramunni A, Brescia P, Dambra P, et al. Effect of low-density lipoprotein apheresis on circulating endothelial progenitor cells in familial hypercholesterolemia. Blood Purification. 2010;29(4):383–389. PubMed

Troutbeck R, Al-Qureshi S, Guymer RH. Therapeutic targeting of the complement system in age-related macular degeneration: a review. Clinical and Experimental Ophthalmology. 2012;40(1):18–26. PubMed

Mahlknecht U, Kaiser S. Age-related changes in peripheral blood counts in humans. Experimental and Therapeutic Medicine. 2010;1(6):1019–1025. PubMed PMC

Twig G, Afek A, Shamiss A, et al. White blood cell count and the risk for coronary artery disease in young adults. PLoS ONE. 2012;7(10)e47183 PubMed PMC

Chen J, Lin L, Lee H, et al. Association of white blood cell count and peripheral arterial disease in patients with and without traditional risk factors. Angiology. 2010;61(4):382–387. PubMed

Bekwelem W, Lutsey PL, Loehr LR, et al. White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) study. Annals of Epidemiology. 2011;21(10):739–748. PubMed PMC

Liu Q, Zhao D, Wang W, et al. The association between white blood cell count and 10-year cardiovascular risk in a large Chinese cohort aged 35–64 years. Zhonghua Xin Xue Guan Bing Za Zhi. 2008;36(5):453–457. PubMed

Macher S, Sipurzynski-Budra S, Rosskopf K, et al. Influence of multicomponent apheresis on donors’ haematological and coagulation parameters, iron storage and platelet function. Vox Sanguinis. 2012;103(3):194–200. PubMed

Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85(10):2720–2730. PubMed

Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. International Journal of Clinical Practice. 2009;63(10):1509–1515. PubMed

Muscari A, Puddu GM, Cenni A, et al. Mean platelet volume (MPV) increase during acute non-lacunar ischemic strokes. Thrombosis Research. 2009;123(4):587–591. PubMed

Bath PMW, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagulation and Fibrinolysis. 1996;7(2):157–161. PubMed

Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis. 2010;8(1):148–156. PubMed PMC

Bath P, Algert C, Chapman N, Neal B. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke. 2004;35(3):622–626. PubMed

Brækkan SK, Mathiesen EB, NjøLstad I, Wilsgaard T, StøRmer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromsø study. Journal of Thrombosis and Haemostasis. 2010;8(1):157–162. PubMed

StudniIka J, Rencová E, Bláha M, et al. Long-term outcomes of rheohaemapheresis in the treatment of dry form of age-related macular degeneration. Journal of Ophthalmology. 2013;2013:8 pages.135798 PubMed PMC